ACW HY26 results - XanaMIA pivotal Alzheimers trial progress
Filed with ASX · · 5 pages · English
Summary by 6ix AI
Actinogen Medical Limited has released its interim financial results for the first half of the financial year, highlighting progress in the XanaMIA pivotal Alzheimer's trial and preparations for commercial readiness. The company completed participant enrollment in the XanaMIA trial and received positive interim safety and efficacy recommendations from the trial's Data Monitoring Committee. Actinogen reported a net loss for the period and outlined significant funding initiatives to support ongoing clinical trials and operations. The company remains optimistic about its prospects, with the next key results from the XanaMIA trial expected in the near future.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Actinogen Medical Limited on 6ix
Story so far
Earlier from Actinogen Medical
- Actinogen HY2025 financial report and Appendix 4D
- ACW receives further $1.9m FY2025 R&D rebate from ATO
- Actinogen receives positive Interim Analysis recommendation from its independent Data Monitoring Committee to continue the XanaMIA pivotal Alzheimer’s disease trial
- ACW secures funding beyond XanaMIA AD trial final results
- ACW December 2025 quarterly activity report & Appendix 4C
Later from Actinogen Medical
- ACW successfully completes $16.8m Placement and SPP
- ACW XanaMIA Alzheimers open label trial commences
- Actinogen commences open-label phase of XanaMIA Alzheimer’s trial and provides business update
- Correction-March2026 quarterly activity report & Appendix 4C
- Actinogen receives positive scientific advice from EMA
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical